Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’

Novo Nordisk’s shares fall sharply after testing of CagriSema falls short of investors’ expectations

Business live – latest updates

The owner of Wegovy and Ozempic has suffered a significant setback, as its highly anticipated new weight-loss treatment was labelled “obsolete” after disappointing clinical trials.

Novo Nordisk’s shares fell sharply on Monday after the results from testing the Danish company’s CagriSema drug fell short of investors’ expectations.

The weekly injection combines an amylin analogue with GLP-1 to regulate the metabolism, suppressing appetite and making users feel full more quickly. This means CagriSema leads to greater weight loss than Novo’s hugely popular Wegovy and Ozempic GLP-1 jabs.